Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1954 4
1955 2
1956 6
1957 1
1958 4
1959 2
1960 1
1961 6
1962 1
1964 1
1965 4
1966 11
1967 11
1968 10
1969 9
1970 21
1971 12
1972 20
1973 29
1974 34
1975 33
1976 41
1977 42
1978 51
1979 65
1980 69
1981 73
1982 68
1983 73
1984 67
1985 71
1986 57
1987 54
1988 70
1989 57
1990 61
1991 62
1992 85
1993 98
1994 94
1995 100
1996 147
1997 153
1998 128
1999 111
2000 118
2001 116
2002 87
2003 134
2004 133
2005 115
2006 121
2007 124
2008 149
2009 110
2010 124
2011 144
2012 125
2013 138
2014 145
2015 163
2016 136
2017 127
2018 92
2019 54
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4,338 results
Results by year
Filters applied: . Clear all
Page 1
Testosterone and Benign Prostatic Hyperplasia.
Rastrelli G, et al. Sex Med Rev 2019 - Review. PMID 30803920
METHODS: Relevant records were retrieved by an extensive search in Medline, including the following keywords ("testosterone"[MeSH Terms] OR "testosterone"[All Fields]) AND ("prostatic hyperplasia"[MeSH Terms] OR ("prostatic"[All Fields] AND "hyperplasia"[All Fields]) OR "prostatic hyperplasia"[All Fields] OR ("benign"[All Fields] AND "prostatic"[All Fields] AND "hyperplasia"[All Fields]) OR "benign prostatic hyperplasia"[All Fields]). ...Testosterone and Benign Prostatic Hyperplasia. Sex Med Rev 2019;7:259-271....
METHODS: Relevant records were retrieved by an extensive search in Medline, including the following keywords ("testosterone"[MeSH Terms] OR …
Inhibition effects of chlorogenic acid on benign prostatic hyperplasia in mice.
Huang Y, et al. Eur J Pharmacol 2017. PMID 28416373
A total of 60 mice were randomly divided into six groups: (Group 1) normal control group, (Group 2) benign prostatic hyperplasia model control group, (Group 3) benign prostatic hyperplasia mice treated with finasteride at a dose of 1mg/kg, (Group 4) benign prostatic hyperplasia mice treated with chlorogenic acid at dose levels of 0.8mg/kg (low dose group), (Group 5) benign prostatic hyperplasia mice treated with chlorogenic acid at dose levels of 1.6mg/kg (medium dose group) and (Group 6) benign prostatic hyperplasia mice treated with chlorogenic acid at dose levels of 3.2mg/kg (high dose group). ...Comparing with benign prostatic hyperplasia model group, the high and medium dose of chlorogenic acid could significantly reduce prostate index and levels of acid phosphatase, prostatic acid phosphatase and typeⅡ5-alpha-reductase (P<0.05 or P<0.01). ...
A total of 60 mice were randomly divided into six groups: (Group 1) normal control group, (Group 2) benign prostatic hyperplasia mode …
Inflammatory mediators in the development and progression of benign prostatic hyperplasia.
De Nunzio C, et al. Nat Rev Urol 2016 - Review. PMID 27686153
Benign prostatic hyperplasia (BPH) is the most common urological disease in elderly men. Epidemiological data suggest a causal link between this condition and prostatic inflammation. ...Several stimuli, including infectious agents, urinary reflux, metabolic syndrome, the ageing process, and autoimmune response, have been described as triggers for the dysregulation of the prostatic immune system via different molecular pathways involving the development of inflammatory infiltrates. ...
Benign prostatic hyperplasia (BPH) is the most common urological disease in elderly men. Epidemiological data suggest a causal link b …
Endocrine control of benign prostatic hyperplasia.
La Vignera S, et al. Andrology 2016 - Review. PMID 27089546 Free article.
Benign prostatic hyperplasia (BPH) is the most common benign proliferative disease among aging men. Androgens play a key role in the development and growth of the male genital tract favoring differentiation and proliferation of stromal and epithelial cells of the prostate gland. ...
Benign prostatic hyperplasia (BPH) is the most common benign proliferative disease among aging men. Androgens play a key role in the …
Inflammation and benign prostatic hyperplasia: clinical implications.
Chughtai B, et al. Curr Urol Rep 2011 - Review. PMID 21519898
Prostatic inflammation may be a large contributor to hyperplastic changes in the prostate. There have been several studies looking at the varieties of growth factors and cytokines that are involved in both the inflammatory process and in the epithelial/stromal prostatic cells interactions. ...This article reviews the factors that lead to both intrinsic and extrinsic causes of prostatic inflammation. There are several exciting studies supporting that inflammation can promote chronic prostatic diseases, such as BPH....
Prostatic inflammation may be a large contributor to hyperplastic changes in the prostate. There have been several studies looking at
Oxidative stress in prostate hyperplasia and carcinogenesis
Udensi UK and Tchounwou PB. J Exp Clin Cancer Res 2016 - Review. PMID 27609145 Free PMC article.
Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH can be classified as benign prostatic hyperplasia (BPH), or prostate cancer (PCa) based on its severity. ...
Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH can be classified as benign prostatic
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Minutoli L, et al. Int J Mol Sci 2016 - Review. PMID 27529214 Free PMC article.
Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. ...
Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract sympt …
Human benign prostatic hyperplasia heterotransplants as an experimental model.
Lopez-Barcons LA. Asian J Androl 2010 - Review. PMID 19946317 Free PMC article.
Benign prostatic hyperplasia is a nonmalignant adenomatous enlargement of the periurethral prostate gland. It is a common disease in older men. In addition to man, spontaneous benign prostatic hyperplasia occurs in chimpanzee and the dog. Alternatives to these spontaneous models are induced benign prostatic hyperplasia, xenografts and in vitro models. ...
Benign prostatic hyperplasia is a nonmalignant adenomatous enlargement of the periurethral prostate gland. It is a common disease in …
Biased α-adrenergic receptor and βarrestin signaling in a cell culture model of benign prostatic hyperplasia.
Wang M, et al. Biochem Biophys Res Commun 2016. PMID 26850854
Benign prostatic hyperplasia (BPH) is a common disease in older men that involves the enlargement of the prostate gland. This occurs in response to signal transduction initiated by α-adrenergic receptors (α-ARs). ...In this study, we aimed to exploit an in vitro model system of BPH in order to better understand the mechanisms of α-AR signaling in prostatic hyperplasia....
Benign prostatic hyperplasia (BPH) is a common disease in older men that involves the enlargement of the prostate gland. This occurs …
Stromal nodules in benign prostatic hyperplasia: morphologic and immunohistochemical characteristics.
Park H, et al. Prostate 2014. PMID 25111578
BACKGROUND: One hundred forty nine stromal nodules (SNs) from transurethral resection of benign prostatic hyperplasia specimens in 39 patients (57-85 years with mean of 70.9) were investigated to characterize the SNs and to outline the etiopathogenesis of solitary fibrous tumors (SFTs) and gastrointestinal stromal tumors (GISTs) of prostate by immunohistochemistry performed on tissue microarray sections. ...Although the cells comprising the SNs seem to be not associated with the origin of prostatic GISTs, there is a possibility of a tentative link of SFTs arising from SNs of the prostate....
BACKGROUND: One hundred forty nine stromal nodules (SNs) from transurethral resection of benign prostatic hyperplasia specimens in 39 …
4,338 results
Jump to page
Feedback